Abstract:
During this webinar, our experts will explore recent developments that highlight the ability to adapt an automated manufacturing platform to different processes, such as positively or negatively selecting T cells directly from apheresis. Automatic transfer to an expansion chamber after isolation for further culturing enables a reduction in manual processing. Enabling direct cell isolation from apheresis eliminates the need for additional upstream processing unit operations, thus reducing costs, time, and space requirements. Cell isolation can be achieved using GMP-grade products that enable flexible process design to achieve specific user requirements.
Speakers: Tamara Laskowski, PhD, Head of Clinical Development, Personalized Medicine; Nuala Trainor, PhD, Head of R&D, Personalized Medicine